Implanon Nxt

Etonogestrel, the active ingredient in Implanon Nxt, is a progestin presented as a 68 mg implant for subcutaneous use. It provides long‑acting hormonal contraception by preventing ovulation and thickening cervical mucus, and is indicated for women of reproductive age seeking reliable pregnancy prevention.

GNH USA supplies Implanon Nxt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to a global network of healthcare providers.

Etonogestrel is a progestin used in hormonal contraception to prevent pregnancy. - Contraception: provides long‑acting reversible birth control for women of reproductive age. - Family planning: enables reliable pregnancy prevention without daily dosing. - Hormonal birth control: maintains suppression of ovulation for up to three years.

Implanon Nxt may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects: - Irregular bleeding or spotting: changes in menstrual pattern are frequent. - Amenorrhea: absence of menstrual bleeding may occur. - Headache: mild to moderate intensity. - Weight gain: modest increase reported by some users. - Acne or oily skin: hormonal changes can affect skin condition. - Breast tenderness: mild discomfort in the breast tissue.

Serious or Rare Side Effects: - Ectopic pregnancy: rare but serious if pregnancy occurs. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Depression or mood changes: significant psychological effects. - Liver dysfunction: abnormal liver enzymes or hepatitis. - Insertion site infection: redness, swelling, or discharge at the implant site.

Before initiating Implanon Nxt, healthcare providers should evaluate patient history and counsel on potential risks. - Contraindications: avoid in women with known thromboembolic disorders or active liver disease. - Screening: assess for pregnancy before insertion; the device is not for use during pregnancy. - Monitoring: advise patients to report severe or persistent headaches, visual changes, or abdominal pain. - Follow‑up: schedule regular check‑ups to assess implant position and menstrual changes. - Storage: Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Etonogestrel may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Rifampin and other strong enzyme inducers: can markedly reduce contraceptive efficacy. - Certain antiepileptic drugs (e.g., carbamazepine, phenytoin): may lower plasma levels of etonogestrel.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., erythromycin, clarithromycin): may modestly decrease effectiveness. - St. John’s wort: herbal supplement that can reduce hormone levels. - Antiretroviral agents (e.g., efavirenz): may require additional contraceptive measures. - Antifungal azoles (e.g., ketoconazole): potential to increase hormone concentrations.